Novo Nordisk Foundation Cluster Lectures 2016 - Series 4
The Novo Nordisk Foundation Cluster Lectures are a series of open lectures for all researchers and other interested in and around the Copenhagen area. Every 4 weeks, on a Thursday evening, you are invited to Tuborg Havnevej for lectures on themes with a general interest for the Novo Nordisk Foundation Research Centers. Often there will be a cross-disciplinary focus. The fourth lecture on 14 April 2016 will give you an insight in how to come further with your innovative ideas if you're aspiring entrepreneurship.
15:45 Welcome and registration (coffee/tea, fruit, water available)
16:00 Claus Nielsen, DTU Innovation and entrepreneurship
“Process and framework for seeking IP protection (at DTU)”
16:30 Andreas Laustsen, co-founder of Biosyntia and VenomAb
"Biotech entrepreneurship - the advantage of being young"
17:00 Arne Nedergaard Kousholt, REBBLS - Rising Entrepreneurs in BioBusiness and Life Sciences
"How can networks help you with innovation and entrepreneurship?"
17:30 Networking with a drink and a bite
18:30 Thank you for a splendid end of day!
Registration is free of charge, but mandatory on our event's website on Eventbrite
SAVE THE DATE
The next Cluster Lecture will take place on 12 May 2016. We look forward to meeting you there too! Do you have a good idea for a theme or inspiring speakers? Contact us at email@example.com
I would like to know more about upcoming Novo Nordisk Foundation Cluster Lectures - where can I find information?
You are very welcome to join the 'Novo Nordisk Foundation Research Centers' Linkedin group. There you will find information about upcoming lectures, and much more. Also, you may want to sign up for the weekly announcement with events and deadlines, sent out by the group manager.
What are my transport/parking options getting to the event?
You can park for free in front or at the side of Tuborg Havnevej 19. If that is full, there is 3 hours free parking in the parking to the Waterfront shopping mall at the end of the road.
Public transport by train to Hellerup station, and/or bus (1A, 21, 166), nearest by bus stop is Tuborg Boulevard.
How do I cancel my participation?
Please help us respecting our speakers, as well keeping track of the numbers and optimize lecture and catering to the audience by cancelling as soon as you know that you exceptionally will not be able to make it. You can either cancel through Eventbrite or send an email to Sophie Labrosse (firstname.lastname@example.org).
Where can I contact the organizer with any questions?
Contact Sophie Labrosse at email@example.com
A SHORT BIO OF THE SPEAKERS
Claus Jørgen Nielsen is managing a team of Business Developers at DTU with the main responsibility of commercializing inventions made by the researchers at the university. The team handles screening of innovative ideas, managing the patent application process and supports commercialization through sales or licensing of IP and through creation of spin-outs. Claus has a Ph.D. degree from DTU and before joining DTU he spent years 25 years in the private business sector with focus on Management, Business Development and commercialization of high-tech products on the international market.
Andreas Laustsen is specialized in antibody discovery and toxicovenomics for development of recombinant antivenoms against snakebite. Andreas holds an M.Sc.Eng in Human Life Science Engineering from the Technical University of Denmark and is to defend his PhD in Molecular and Cellular Pharmacology from the University of Copenhagen the 3rd of May 2016. Andreas is a co-founder of the biotech companies Biosyntia, VenomAb, and Antag, and he is also recognized as Denmark’s Coolest Engineer (Engineer The Future, DK) and a Leader of Tomorrow (Global Biotech Revolution, UK).
Arne Nedergaard Kousholt currently works as a postdoc both at the Netherlands Cancer Institute (NKI) in
Amsterdam, and as a guest researcher at the Biotech, Research and Innovation Centre (BRIC), university of Copenhagen. He holds a PhD in basic research within cancer biology from the University of Copenhagen. Arne’s next step in research is fuelled by an ambition to apply his scientific background in translational breast cancer research. The dream is to identify therapeutic targets that can be the foundation for a spin out company. In addition to his academic carrier, Arne has experience as a shareholder in an IT start-up company (ChurchDesk), and from various events and volunteer projects including the biotech innovation and entrepreneurship network REBBLS where Arne has been a member of the core-group for 2 years.